CFO of U.S. Bio Company Cashes Out $16.5 Million After Exercising Stock Options in Two Days

On April 27 and 30, United Therapeutics Corp. (NASDAQ: UTHR) Chief Financial Officer James Edgemond exercised 20,000 stock options and sold an equal number of common shares on the open market, realizing approximately $11 million in proceeds. On the same day, Chairman and CEO Martin Rosblatt, under a Rule 10b5-1 trading plan, exercised 9,500 options and sold all resulting shares, netting roughly $5.4–5.5 million. Filings showed that Edgemond’s direct holdings fell from about 28,000 shares to around 18,000 shares following the transactions.

On May 15, the U.S. Food and Drug Administration granted United Therapeutics clearance to begin clinical trials of UHeart, its genetically engineered pig-heart xenotransplantation candidate. Earlier in May, the company reported first-quarter 2026 revenue of approximately $780 million and net income of about $270 million. In March, the board approved a share repurchase program of up to $2 billion and executed a substantial pre-purchase of shares through an accelerated share repurchase agreement.

Founded in 1996 and listed on NASDAQ, United Therapeutics is a biotechnology company specializing in treatments for rare and serious diseases—such as pulmonary arterial hypertension—and in organ-replacement technologies. Headquartered in Silver Spring, Maryland, and Research Triangle Park, North Carolina, the company operates as a public-benefit corporation with a long-term mission to address organ shortages. CEO Martin Rosblatt is also known as the founder of the satellite radio service Sirius.